• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Catherine Hollingsworth

Articles by Catherine Hollingsworth

Knopp to Bring in Potential $345M in ALS Drug Deal

Aug. 19, 2010
By Catherine Hollingsworth

Emergent Plans to Diversify and Buy Trubion for $135.5M

Aug. 16, 2010
By Catherine Hollingsworth
Anthrax vaccine maker Emergent BioSolutions Inc. took steps to expand beyond the realm of biodefense, making plans to buy Seattle-based protein therapeutics specialist Trubion Pharmaceuticals Inc. for approximately $96.8 million up front, plus a potential $38.7 million in milestones for a total potential value of $135.5 million. (BioWorld Today)
Read More

Mercator Arrives at the Right Zip Code With $2M in Hand

Aug. 13, 2010
By Catherine Hollingsworth
Mercator Therapeutics Inc. raised $2 million in seed financing from eight unnamed investors, according to documents filed with the SEC, and licensed technology from the University of Texas M.D. Anderson Cancer Center to develop cancer drugs using a first-of-its-kind technology, the company stated. (BioWorld Today)
Read More

Alectos to Study Alzheimer's Target in Merck $289M Deal

Aug. 12, 2010
By Catherine Hollingsworth
Alectos Therapeutics Inc. will receive up to $289 million in an up-front fee and milestone payments under a collaboration with Merck & Co. to study a potential non-amyloid approach to treat Alzheimer's disease. (BioWorld Today)
Read More

Endo to Acquire Penwest for $168M, Cutting Royalty Stream

Aug. 11, 2010
By Catherine Hollingsworth
Penwest Pharmaceuticals Co. said that Endo Pharmaceuticals Inc., its longtime partner for pain drug Opana ER, has agreed to acquire all the common stock of Penwest for $5 per share in cash, in a deal worth approximately $168 million in total equity value. (BioWorld Today)
Read More

Proximagen Sells Clinical-Stage Compound in $51M Deal

Aug. 11, 2010
By Catherine Hollingsworth

Curis Partners to Analyze Ovarian Cancer Candidate

Aug. 10, 2010
By Catherine Hollingsworth

NuPathe Latest to Price IPO in Trickle of Firms Going Public

Aug. 9, 2010
By Catherine Hollingsworth

NewCo News: Sweden's BioChromix Pharma Tackles AD's Amyloid Cascade

Aug. 6, 2010
By Catherine Hollingsworth

Proximagen Sells Clinical-Stage Compound in $51M Deal

Aug. 5, 2010
By Catherine Hollingsworth
Previous 1 2 3 4 5 6 7 8 9 … 64 65 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 30, 2025.
  • Heart, artery with cholesterol, brain

    In Broadway trial, a hopeful tune for Alzheimer’s prevention

    BioWorld
    At the 2025 Alzheimer’s Association International Conference (AAIC), one of the bigger splashes was made by a cardiovascular drug. In a presentation on July 30,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 29, 2025
  • Illustration of Microglia cells (red) in Alzheimer´s disease

    Two cancer drugs combined modify Alzheimer’s disease in mice

    BioWorld
    Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe